Levodopa unresponsive symptoms in Parkinson disease
Identifieur interne : 002785 ( Main/Exploration ); précédent : 002784; suivant : 002786Levodopa unresponsive symptoms in Parkinson disease
Auteurs : Kapil Sethi [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2008.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Anxiety (epidemiology), Depression (epidemiology), Dyskinesia, Drug-Induced (diagnosis), Female, Gait Disorders, Neurologic (epidemiology), Humans, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Parkinson disease, Sexual Dysfunction, Physiological (epidemiology), Sleep Disorders (epidemiology), Sweating (drug effects), Xerostomia (chemically induced), levodopa, nonmotor symptoms, parkinson's disease.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- chemically induced : Xerostomia.
- diagnosis : Dyskinesia, Drug-Induced.
- drug effects : Sweating.
- drug therapy : Parkinson Disease.
- epidemiology : Anxiety, Depression, Gait Disorders, Neurologic, Sexual Dysfunction, Physiological, Sleep Disorders.
- physiopathology : Parkinson Disease.
- psychology : Parkinson Disease.
- Female, Humans, Male.
Abstract
Levodopa has been the mainstay of symptomatic therapy for Parkinson Disease (PD) for 40 years providing benefit to virtually all patients. Levodopa therapy results in improved activities of daily living, enhanced quality of life, and improved mortality. However, the long‐term use of levodopa is associated with the development of motor fluctuations and dyskinesia. In addition, levodopa therapy has further limitations. It has little or no effect on certain motor features (e.g. gait and balance dysfunction) and a non‐motor symptom complex (autonomic dysfunction, pain syndromes, sleep disorders, mood disturbances, dementia). Further, multiple case reports illustrate the potential of levodopa and other dopaminergic agents to cause or reveal a series of impulse control disorders. This review highlights the levodopa unresponsive symptoms in PD. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22049
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001164
- to stream Istex, to step Curation: 001164
- to stream Istex, to step Checkpoint: 001341
- to stream PubMed, to step Corpus: 002051
- to stream PubMed, to step Curation: 002051
- to stream PubMed, to step Checkpoint: 002236
- to stream Ncbi, to step Merge: 002312
- to stream Ncbi, to step Curation: 002312
- to stream Ncbi, to step Checkpoint: 002312
- to stream Main, to step Merge: 003363
- to stream PascalFrancis, to step Corpus: 001129
- to stream PascalFrancis, to step Curation: 001B90
- to stream PascalFrancis, to step Checkpoint: 001209
- to stream Main, to step Merge: 003817
- to stream Main, to step Curation: 002785
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa unresponsive symptoms in Parkinson disease</title><author><name sortKey="Sethi, Kapil" sort="Sethi, Kapil" uniqKey="Sethi K" first="Kapil" last="Sethi">Kapil Sethi</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AA538F1C3AF899A9F2F2D87BC90503E27C0132C6</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22049</idno><idno type="url">https://api.istex.fr/document/AA538F1C3AF899A9F2F2D87BC90503E27C0132C6/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001164</idno><idno type="wicri:Area/Istex/Curation">001164</idno><idno type="wicri:Area/Istex/Checkpoint">001341</idno><idno type="wicri:doubleKey">0885-3185:2008:Sethi K:levodopa:unresponsive:symptoms</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18781679</idno><idno type="wicri:Area/PubMed/Corpus">002051</idno><idno type="wicri:Area/PubMed/Curation">002051</idno><idno type="wicri:Area/PubMed/Checkpoint">002236</idno><idno type="wicri:Area/Ncbi/Merge">002312</idno><idno type="wicri:Area/Ncbi/Curation">002312</idno><idno type="wicri:Area/Ncbi/Checkpoint">002312</idno><idno type="wicri:Area/Main/Merge">003363</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:08-0466165</idno><idno type="wicri:Area/PascalFrancis/Corpus">001129</idno><idno type="wicri:Area/PascalFrancis/Curation">001B90</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001209</idno><idno type="wicri:doubleKey">0885-3185:2008:Sethi K:levodopa:unresponsive:symptoms</idno><idno type="wicri:Area/Main/Merge">003817</idno><idno type="wicri:Area/Main/Curation">002785</idno><idno type="wicri:Area/Main/Exploration">002785</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa unresponsive symptoms in Parkinson disease</title><author><name sortKey="Sethi, Kapil" sort="Sethi, Kapil" uniqKey="Sethi K" first="Kapil" last="Sethi">Kapil Sethi</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Medical College of Georgia, Augusta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008">2008</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">S3</biblScope><biblScope unit="page" from="S521">S521</biblScope><biblScope unit="page" to="S533">S533</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">AA538F1C3AF899A9F2F2D87BC90503E27C0132C6</idno><idno type="DOI">10.1002/mds.22049</idno><idno type="ArticleID">MDS22049</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Anxiety (epidemiology)</term><term>Depression (epidemiology)</term><term>Dyskinesia, Drug-Induced (diagnosis)</term><term>Female</term><term>Gait Disorders, Neurologic (epidemiology)</term><term>Humans</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Nervous system diseases</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (psychology)</term><term>Parkinson disease</term><term>Sexual Dysfunction, Physiological (epidemiology)</term><term>Sleep Disorders (epidemiology)</term><term>Sweating (drug effects)</term><term>Xerostomia (chemically induced)</term><term>levodopa</term><term>nonmotor symptoms</term><term>parkinson's disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Xerostomia</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Sweating</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Anxiety</term><term>Depression</term><term>Gait Disorders, Neurologic</term><term>Sexual Dysfunction, Physiological</term><term>Sleep Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Male</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Lévodopa</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa has been the mainstay of symptomatic therapy for Parkinson Disease (PD) for 40 years providing benefit to virtually all patients. Levodopa therapy results in improved activities of daily living, enhanced quality of life, and improved mortality. However, the long‐term use of levodopa is associated with the development of motor fluctuations and dyskinesia. In addition, levodopa therapy has further limitations. It has little or no effect on certain motor features (e.g. gait and balance dysfunction) and a non‐motor symptom complex (autonomic dysfunction, pain syndromes, sleep disorders, mood disturbances, dementia). Further, multiple case reports illustrate the potential of levodopa and other dopaminergic agents to cause or reveal a series of impulse control disorders. This review highlights the levodopa unresponsive symptoms in PD. © 2008 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Géorgie (États-Unis)</li></region></list><tree><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Sethi, Kapil" sort="Sethi, Kapil" uniqKey="Sethi K" first="Kapil" last="Sethi">Kapil Sethi</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002785 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002785 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:AA538F1C3AF899A9F2F2D87BC90503E27C0132C6
|texte= Levodopa unresponsive symptoms in Parkinson disease
}}
| This area was generated with Dilib version V0.6.23. |  |